MedPath

Materialise

🇺🇸United States
Ownership
-
Employees
2.4K
Market Cap
-
Website
Introduction

Materialise NV engages in the provision of additive manufacturing software and 3D printing services. It operates through the following segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software worldwide through programs and platforms that enable companies to set up reliable and sustainable 3D printing production. The Materialise Medical segment includes medical software solutions, medical devices and other related products and services. The Materialise Manufacturing segment provides 3D printed services to industrial and commercial customers. The company was founded by Wilfried Vancraen and Hilde Ingelaere on June 28, 1990 and is headquartered in Leuven, Belgium.

FDA Clinical Trial Launches for Revolutionary 3D-Printed Airway Device to Treat Infant Breathing Disorder

• Michigan Medicine and Materialise initiate an eight-year clinical trial to evaluate 3D-printed bioresorbable airway splints for treating severe tracheobronchomalacia in infants, marking a crucial step toward FDA approval. • The groundbreaking device, successfully used in over 40 emergency cases at U-M Health Mott Children's Hospital, is designed to grow with patients and safely dissolve over time. • The multi-center trial aims to enroll 35 infants across five children's hospitals, with Materialise manufacturing the customized devices at their Ann Arbor facility.
© Copyright 2025. All Rights Reserved by MedPath